EMEND Drug Patent Profile

When do Emend patents expire, and when can generic versions of Emend launch?

Emend is a drug marketed by MSD, Msd Merck Co, and Merck And Co Inc. and is included in three NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has forty-eight patent family members in thirty-seven countries.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emend

A generic version of EMEND was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9^th, 2016.

Summary for EMEND

International Patents:	48
US Patents:	1
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,349
Drug Prices:	Drug price information for EMEND
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EMEND
What excipients (inactive ingredients) are in EMEND?	EMEND excipients list
DailyMed Link:	EMEND at DailyMed

See drug prices for EMEND

Pharmacology for EMEND

Drug Class	Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists

Paragraph IV (Patent) Challenges for EMEND

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMEND	for Oral Suspension	aprepitant	125 mg/Kit	207865	1	2016-11-23
EMEND	Injection	fosaprepitant dimeglumine	150 mg/vial	022023	2	2012-01-25
EMEND	Capsule	aprepitant	40 mg, 80 mg and 125 mg	021549	1	2008-11-03

US Patents and Regulatory Information for EMEND

EMEND is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006		DISCN	Yes	No	8,258,132		Y
Msd Merck Co	EMEND	aprepitant	FOR SUSPENSION;ORAL	207865-001	Dec 17, 2015		RX	Yes	Yes	8,258,132		Y
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-001	Jan 25, 2008		DISCN	Yes	No
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003	AB	RX	Yes	No	8,258,132		Y
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-002	Mar 26, 2003	AB	RX	Yes	Yes	8,258,132		Y
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010	AP	RX	Yes	Yes

Expired US Patents for EMEND

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	7,214,692
Merck And Co Inc	EMEND	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	022023-002	Nov 12, 2010	5,512,570
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-002	Mar 26, 2003	6,048,859
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	5,719,147
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003	7,214,692
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	5,145,684
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006	6,235,735

EU/EMA Drug Approvals for EMEND

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Emend	aprepitant	EMEA/H/C/000527Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.	Authorised	no	no	no	2003-11-11

International Patents for EMEND

See the table below for patents covering EMEND around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	9800216
Australia	701862
Brazil	9810360
Japan	3245424
Poland	180522
Germany	69326977
Hungary	T70952

Supplementary Protection Certificates for EMEND

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	CA 2004 00009	Denmark
0734381	91069	Luxembourg		91069, EXPIRES: 20181111
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381	PA2004002	Lithuania		PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0748320	08C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381	SPC005/2004	Ireland		SPC005/2004: 20050504, EXPIRES: 20181110
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111

EMEND (aprepitant): Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is EMEND’s market position?

EMEND is the brand name for aprepitant, a neurokinin-1 (NK1) receptor antagonist used primarily with 5-HT3 antagonists and corticosteroids to prevent chemotherapy-induced nausea and vomiting (CINV). Market dynamics for EMEND have been shaped by (1) the structure of CINV prophylaxis regimens, (2) entry of generics after patent expiry, and (3) ongoing shifts in payer and channel economics tied to guideline adoption and formulary design.

How did EMEND’s financial trajectory typically evolve post-launch?

A predictable pattern has played out across therapeutic brands in CINV: branded uptake after launch, then a multi-year decline after patent/market exclusivity ends as lower-cost competitors enter. EMEND follows that standard commercialization arc, with additional pressure from:

• Generic aprepitant entering and taking share in standard CINV prophylaxis settings.
• Compound economics: aprepitant is used in combination, so formularies can substitute at the single-agent level without changing the regimen framework.
• Channel contracting: rebates and pricing pressure increase as exclusivity erodes.

Net result: EMEND’s revenue has trended down over time as generic penetration increased, with any remaining branded demand concentrated in accounts that retain brand preferences due to contracting terms or formulary path dependency.

What are the key market forces shaping CINV demand for aprepitant?

CINV incidence, regimen standardization, and payer policy define demand more than marketing:

• Guideline-driven regimen behavior: CINV prophylaxis is protocolized, which increases the predictability of agent-level demand.
• Use intensity by chemo emetogenicity: aprepitant use scales with the mix of chemotherapy that triggers guideline prophylaxis.
• Switch incentives at the molecule level: when a single component goes generic, payers can maintain regimen equivalence while lowering acquisition cost.

Where did EMEND face pricing and share pressure?

Pressure concentrates where formularies have the most leverage:

• Large retail and PBM formularies: higher likelihood of substitution once generics are available.
• Hospital contracting: group purchasing organizations (GPOs) often drive selection toward the lowest total cost option, especially for widely used supportive care.

The net financial effect is that branded aprepitant is capped by generic availability and the contracting environment, even if clinical use remains guideline-aligned.

What competitive dynamics emerged as generics arrived?

Once generic aprepitant is listed and stocked, the competitive set becomes price-driven:

• Brand premium compression: payers and providers can switch without changing the regimen’s clinical structure.
• Incremental switching: switching tends to accelerate after initial formulary updates, then stabilizes as contracts reset.
• Brand survival pockets: some accounts may keep the brand due to contract terms, physician preference history, or administrative friction, but these generally shrink over time.

How does aprepitant’s formulation and regimen fit affect economics?

EMEND’s economics are influenced by how it is delivered within prophylaxis:

• Core molecule role: NK1 antagonism remains a recognized component of multi-agent CINV prevention, but it does not protect the branded molecule once generic options exist.
• Regimen bundling: total regimen cost often becomes the basis for payer decisions, giving generic aprepitant a direct cost advantage.

What does the financial trajectory imply for investors and R&D planners?

The investment logic for supportive-care brands like EMEND is dominated by:

• Exclusivity duration and the timing of generic entry.
• Contracting outcomes (brand retained vs. substitution in covered lives).
• Channel turnover speed (how quickly formularies and GPOs adopt the lowest-cost equivalent).

For R&D strategy, the implication is clear: in mature supportive-care segments with established regimens, durable value depends less on clinical differentiation alone and more on protection against generic substitution (stronger IP, reformulation strategy, or differentiated product line extensions).

---

Key market-dynamics checklist (aprepitant/CINV)

Driver	Market impact	Branded EMEND effect
Guideline standardization of CINV prophylaxis	Stabilizes agent-level demand patterns	Maintains baseline use until generic substitution accelerates
Generic entry for aprepitant	Converts brand into price competition	Drives revenue decline and margin compression
Payer formulary and contracting leverage	Increases substitution speed	Reduces branded market share in covered settings
Regimen economics vs. single-agent economics	Total regimen cost becomes decisive	Shifts preference to lowest-cost equivalent in combinations

---

Key Takeaways

• EMEND (aprepitant) has a stable clinical role in CINV prophylaxis, but its financial trajectory is constrained by generic substitution dynamics once exclusivity expires.
• Market demand persists because NK1 antagonism is guideline-aligned, yet branded revenues compress sharply as generics enter payers and channels.
• The dominant determinants of future EMEND-like trajectories are exclusivity timing, formulary behavior, and contracting speed, not trial-driven demand expansion.

---

FAQs

1) What is EMEND used for?

EMEND (aprepitant) is used for prevention of chemotherapy-induced nausea and vomiting (CINV) as part of multi-agent prophylaxis.

2) What drives EMEND revenue over time?

Revenue is driven first by branded uptake post-launch, then declines as generic aprepitant expands in payer formularies and pharmacy channels.

3) Does aprepitant’s clinical role end after generic entry?

No. Generic entry typically affects pricing and market share, while the supportive-care role remains in guideline-based regimens.

4) Why does combination-regimen use matter economically?

Because CINV prophylaxis is multi-agent, payers can substitute at the single-agent level, especially when regimen equivalence is preserved.

5) What is the most important factor for brand survival in mature CINV markets?

Contracting and formulary outcomes after generic listing determine whether a brand keeps residual share or rapidly shifts to lowest-cost alternatives.

---

References

[1] FDA. “EMEND (aprepitant) Prescribing Information.” U.S. Food and Drug Administration.
[2] National Comprehensive Cancer Network (NCCN). “Nausea and Vomiting” (CINV Guidelines). Latest version available at publication.
[3] European Society for Medical Oncology (ESMO). “Management of chemotherapy-induced nausea and vomiting” (guideline documents).

(No additional sources were used beyond those cited above.)